Phathom Pharmaceuticals Inc (PHAT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Phathom Pharmaceuticals Inc (PHAT) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.12 Million) by net assets ($-422.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Phathom Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Phathom Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Phathom Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Phathom Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phathom Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen MYS Environmental Protection & Technology Co Ltd
SHE:002303
|
0.003x |
|
E2E Networks Limited
NSE:E2E
|
0.020x |
|
Cera Sanitaryware Limited
NSE:CERA
|
0.052x |
|
Shenzhen Sea Star Technology
SHE:002137
|
0.031x |
|
Ryerson Holding Corp
NYSE:RYI
|
0.148x |
|
Zhengping Road&Bridge Constr
SHG:603843
|
-0.011x |
|
Camden National Corporation
NASDAQ:CAC
|
0.028x |
|
Wuxi Longsheng Technology Co Ltd
SHE:300680
|
0.055x |
Annual Cash Flow Conversion Efficiency for Phathom Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Phathom Pharmaceuticals Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Phathom Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-253.58 Million | $-266.77 Million | 1.052x | -44.36% |
| 2023-12-31 | $-72.76 Million | $-137.58 Million | 1.891x | -3.46% |
| 2022-12-31 | $-74.81 Million | $-146.53 Million | 1.959x | +195.20% |
| 2021-12-31 | $72.16 Million | $-148.46 Million | -2.057x | -473.56% |
| 2020-12-31 | $194.27 Million | $-69.69 Million | -0.359x | -123.97% |
| 2019-12-31 | $227.96 Million | $-36.51 Million | -0.160x | -120.13% |
| 2018-12-31 | $-1.29 Million | $-1.02 Million | 0.795x | -- |
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t… Read more